Literature DB >> 18394834

Relationship between dissolution efficiency of Oxazepam/carrier blends and drug and carrier molecular descriptors using multivariate regression analysis.

Annalisa Cutrignelli1, Angela Lopedota, Adriana Trapani, Giancarlo Boghetich, Massimo Franco, Nunzio Denora, Valentino Laquintana, Giuseppe Trapani.   

Abstract

Quantitative structure-property relationships were developed for predicting the enhancement of dissolution rate of the model lipophilic drug Oxazepam (Oxa) from blends (BLs) with 12 structurally different carriers at three different drug/carrier weight ratios (1/5, 1/10, and 1/20). To this end, 36 BLs were prepared by the solvent-evaporation method and characterized by spectroscopic (FT-IR), thermoanalytical (DSC) and X-ray diffraction studies. The dissolution rate of the examined systems was quantified by logDE/DE(Oxa), where DE and DE(Oxa) are the dissolution efficiencies of the BL and pure drug, respectively. Twenty molecular descriptors, including parameters for size, lipophilicity, cohesive energy density (CED), and hydrogen bonding capacity were calculated and together with the experimental melting point (MP), were used in multivariate analysis. Twelve pertinent variables were detected after looking at the results of principal component analysis (PCA) and cluster analysis, and reliable six-descriptor models generated by Partial Least Squares-Projection to Latent Structures (PLS) method. Satisfactory coefficient of determination values were obtained (i.e., R(2) equal to 0.794 and Q(2) equal to 0.705). The equations generated can predict with reasonable accuracy the dissolution rate increase of the model lipophilic drug/carrier BLs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18394834     DOI: 10.1016/j.ijpharm.2008.02.018

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Griseofulvin/carrier blends: application of partial least squares (PLS) regression analysis for estimating the factors affecting the dissolution efficiency.

Authors:  Annalisa Cutrignelli; Adriana Trapani; Angela Lopedota; Massimo Franco; Delia Mandracchia; Nunzio Denora; Valentino Laquintana; Giuseppe Trapani
Journal:  AAPS PharmSciTech       Date:  2011-08-09       Impact factor: 3.246

2.  Hydroxy-Propil-β-Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic Cancer Cell Models.

Authors:  Rosa Maria Iacobazzi; Annalisa Cutrignelli; Angela Stefanachi; Letizia Porcelli; Angela Assunta Lopedota; Roberta Di Fonte; Antonio Lopalco; Simona Serratì; Valentino Laquintana; Nicola Silvestris; Massimo Franco; Saverio Cellamare; Francesco Leonetti; Amalia Azzariti; Nunzio Denora
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

3.  Delivery of Proapoptotic Agents in Glioma Cell Lines by TSPO Ligand-Dextran Nanogels.

Authors:  Antonio Lopalco; Annalisa Cutrignelli; Nunzio Denora; Mara Perrone; Rosa Maria Iacobazzi; Elisabetta Fanizza; Angela Lopedota; Nicoletta Depalo; Modesto de Candia; Massimo Franco; Valentino Laquintana
Journal:  Int J Mol Sci       Date:  2018-04-11       Impact factor: 5.923

4.  Dasatinib/HP-β-CD Inclusion Complex Based Aqueous Formulation as a Promising Tool for the Treatment of Paediatric Neuromuscular Disorders.

Authors:  Annalisa Cutrignelli; Francesca Sanarica; Antonio Lopalco; Angela Lopedota; Valentino Laquintana; Massimo Franco; Brigida Boccanegra; Paola Mantuano; Annamaria De Luca; Nunzio Denora
Journal:  Int J Mol Sci       Date:  2019-01-30       Impact factor: 5.923

5.  Reproducibility warning: The curious case of polyethylene glycol 6000 and spheroid cell culture.

Authors:  Simona Serrati; Chiara Martinelli; Antonio Palazzo; Rosa Maria Iacobazzi; Mara Perrone; Quy K Ong; Zhi Luo; Ahmet Bekdemir; Giulia Pinto; Ornella Cavalleri; Annalisa Cutrignelli; Valentino Laquintana; Nunzio Denora; Francesco Stellacci; Silke Krol
Journal:  PLoS One       Date:  2020-03-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.